Redhill Biopharma Ltd
NASDAQ:RDHL

Watchlist Manager
Redhill Biopharma Ltd Logo
Redhill Biopharma Ltd
NASDAQ:RDHL
Watchlist
Price: 1.71 USD -15.35% Market Closed
Market Cap: 3.9m USD

Net Margin
Redhill Biopharma Ltd

-102.8%
Current
-6%
Average
5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-102.8%
=
Net Income
-8.3m
/
Revenue
8m

Net Margin Across Competitors

Redhill Biopharma Ltd
Glance View

Market Cap
3.9m USD
Industry
Pharmaceuticals

RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.

RDHL Intrinsic Value
8.59 USD
Undervaluation 80%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

Summary
RDHL intrinsic value, competitors valuation, and company profile.
DCF Valuation
RDHL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RDHL stock valuation using valuation multiples.
Wall Street Estimates
RDHL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RDHL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-102.8%
=
Net Income
-8.3m
/
Revenue
8m
What is the Net Margin of Redhill Biopharma Ltd?

Based on Redhill Biopharma Ltd's most recent financial statements, the company has Net Margin of -102.8%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 270,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.